NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Oruka Therapeutics, Inc. (ORKA) Stock Analysis

Oruka Therapeutics, Inc. (ORKA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ORKA

$92.51

+$1.52 (+1.67%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ORKA with… →

ORKA Key Statistics

As of Sep 4, 2026
Trading
Open
$90.06
Previous Close
$90.99
Day's Range
89.38–94.00
52-Week Range
14.67–115.52
Volume
600.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.21
Valuation
Market Cap
$6.13B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.07
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$105.43M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
66.21M
1-Year Return
+517.97%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
1.19M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ORKA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+205.21%
2025+56.32%
2024+76.73%
2023−28.27%
2022+10.23%
2021−46.38%
2020−29.77%
2019−3.87%
2018−75.56%
2017−52.63%
2016 (partial year)−7.17%

As of September 4, 2026.

ORKA Valuation vs Biotechnology Median

Median of 656 stocks
MetricORKABiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Oruka Therapeutics, Inc. (ORKA) carries a market capitalisation of $6.13B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 68.

ORKA last closed at $92.51 on September 4, 2026. That is +$1.52 (+1.67%) against the previous close. The 52-week range on file runs from $14.67 to $115.52. The latest close sits 530.61% above that 52-week low.

Financial Health

In fiscal 2025, Oruka Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $105.43M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −2.07.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at −0.21. Daily returns over the trailing 10 years annualize to a volatility of 152.67%. The trailing one-year price return is +517.97%. Measured over 10 years, that is −12.06% a year compounded.

Growth & Income

The record shows no dividend for ORKA.

The strongest complete calendar year on file is 2024 at +76.73%; the weakest is 2018 at −75.56%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the price is +205.21%.

Peer Comparison

Oruka Therapeutics, Inc. (ORKA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Oruka Therapeutics, Inc. ORKA $6.13B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Oruka Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Visit website →